Nature Reviews Drug Discovery (2020) https://doi.org/10.1038/s41573-019-0056-x Published online 14 February 2020
In the subsection on post-licensure considerations, the authors wish to clarify that accelerated licensure granted for high-dose trivalent influenza vaccine was independent of the 2009 H1N1 outbreak, and the randomized controlled trial in approximately 31,000 adults 65 years of age and older showed that the high-dose influenza vaccine demonstrated clear superior efficacy relative to the standard-dose vaccine210. Text in this subsection has been modified accordingly.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wei, CJ., Crank, M.C., Shiver, J. et al. Author Correction: Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov 19, 427 (2020). https://doi.org/10.1038/s41573-020-0066-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41573-020-0066-8